#Germany #Berlin #Coreline Soft #Lung Cancer Screening #Charité

Coreline Soft Strengthens Lung Cancer Screening in Berlin

In a groundbreaking moment for lung cancer detection, Coreline Soft, a prominent player in medical AI, has partnered with Charité – Universitätsmedizin Berlin to implement its state-of-the-art lung cancer screening solution. This collaboration marks Coreline's official entry into a crucial clinical center within Germany's national lung cancer screening framework, which predominantly utilizes low-dose computed tomography (LDCT).

Introduction of AVIEW LCS Plus

The centerpiece of this partnership is Coreline Soft's innovative AVIEW LCS Plus product, designed to enhance the efficacy of lung cancer screening through advanced CT technology. This solution offers automatic analysis of pulmonary nodules, chronic obstructive pulmonary disease (COPD), and coronary artery calcification (CAC), all from a single imaging exam. Such integration not only boosts efficiency but also maintains consistency in diagnostic readings, addressing one of the primary challenges in lung cancer screening today.

Proven Reliability Through Rigorous Validation

Coreline Soft's technology has been rigorously validated through the HANSE project, a national screening pilot in Germany, which has demonstrated the solution's operational stability across multiple clinical environments. This validation underscores the credibility of the AVIEW LCS Plus in real-world scenarios, offering reassurance to healthcare providers and patients alike regarding its effectiveness and trustworthiness.

Shift from Pilot to National Screening

Germany is transitioning from pilot initiatives to a formalized national lung cancer screening program. By mid-2026, the Federal Joint Committee (G-BA) plans to integrate low-dose CT screening into mandatory health insurance offerings. This evolution signifies a move toward standardized procedures, encompassing participant selection, dual readings, and quality control, departing from the previously fragmented adoption seen in various institutions.

AVIEW HUB: Centralized Screening Operations

To meet the stringent requirements of dual reading protocols and data pseudonymization, Coreline Soft has introduced the AVIEW HUB platform. This centralized system seamlessly integrates various quality control functions, ensuring regulatory compliance while significantly reducing the manual workload for medical personnel. By streamlining operations, AVIEW HUB enhances the overall efficiency of lung cancer screenings, making it easier for healthcare providers to deliver timely and accurate diagnostics.

Competitive Advantages in the Market

Industry experts believe that Charité's adoption of Coreline’s technology signifies a shift in the lung cancer screening landscape from a focus on product performance to operational infrastructure competition. As national reimbursement systems stabilize and processes become standardized, Coreline Soft, with its experience in centralized management and multicentric operations, is set to strengthen its competitive edge in the global market. This strategic positioning will likely enhance the company's prospects as it navigates the evolving landscape of medical diagnostics.

Conclusion

The collaboration between Coreline Soft and Charité embodies a significant advancement in the fight against lung cancer, leveraging cutting-edge AI technology to improve screening accuracy and efficiency. As Germany moves toward a comprehensive national lung cancer screening program, the integration of such innovative solutions is crucial for enhancing patient outcomes and streamlining healthcare delivery. Coreline Soft is not just contributing to this important health initiative; it is setting a precedent for how technology can revolutionize cancer diagnosis and treatment in the future.